The importance of HCV RNA measurement for tailoring treatment duration

Digestive and Liver Disease

Volumn 45, Issue S5, 2013, Pages

  Peiffer, Kai Henrik ^a   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

BDNA; LLOD; LLOQ; Realtime PCR; TMA; Triple therapy

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

COMBINATION CHEMOTHERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PATIENT MONITOR; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS GENE; VIRUS TYPING;

BDNA; LLOD; LLOQ; REALTIME-PCR; TMA; TRIPLE-THERAPY;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIMIT OF DETECTION; POLYMERASE CHAIN REACTION; PROTEASE INHIBITORS; RNA, VIRAL; TIME FACTORS;

EID: 84884717559     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.007     Document Type: Review

References (60)

1. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
2. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1195-1206.
3. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011, 364:2405-2416.
4. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
5. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011, 365:1014-1024.
6. Leroy V., Serfaty L., Bourliere M., et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver International 2012, 32:1477-1492.
7. Sarrazin C., Berg T., Cornberg M., et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Zeitschrift fur Gastroenterologie 2012, 50:57-72.
8. Ghany M.G., Nelson D.R., Strader D.B., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
9. Chevaliez S., Rodriguez C., Pawlotsky J.M. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012, 142:1303 e1-1313 e1.
10. Vermehren J., Kau A., Gartner B.C., et al. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. Journal of Clinical Microbiology 2008, 46:3880-3891.
11. Chevaliez S., Bouvier-Alias M., Pawlotsky J.M. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. Journal of Clinical Microbiology 2009, 47:1726-1732.
12. Fytili P., Tiemann C., Wang C., et al. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. Journal of Clinical Virology 2007, 39:308-311.
13. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, 55:245-264.
14. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
15. Saldanha J., Lelie N., Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA, WHO Collaborative Study Group. Vox Sanguinis 1999, 76:149-158.
16. Saldanha J., Heath A., Aberham C., et al. World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sanguinis 2005, 88:202-204.
17. Pawlotsky J.M. Molecular diagnosis of viral hepatitis. Gastroenterology 2002, 122:1554-1568.
18. COBAS® AMPLICOR® HCV MONITOR Test v. Package insert. Volume Revision 10.0; 2009.
19. Konnick E.Q., Erali M., Ashwood E.R., et al. Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0. International Unit assay and the National Genetics Institute HCV Superquant assay. Journal of Clinical Microbiology 2002, 40:768-773.
20. Lee S.C., Antony A., Lee N., et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. Journal of Clinical Microbiology 2000, 38:4171-4179.
21. Morishima C., Chung M., Ng K.W., et al. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. Journal of Clinical Microbiology 2004, 42:421-425.
22. Morishima C., Morgan T.R., Everhart J.E., et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006, 44:360-367.
23. Gorrin G., Friesenhahn M., Lin P., et al. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. Journal of Clinical Microbiology 2003, 41:310-317.
24. Sarrazin C., Gartner B.C., Sizmann D., et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1-5. Journal of Clinical Microbiology 2006, 44:729-737.
25. Chevaliez S., Bouvier-Alias M., Brillet R., et al. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007, 46:22-31.
26. Chevaliez S., Bouvier-Alias M., Castera L., et al. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 2009, 49:1397-1398.
27. Zitzer H., Heilek G., Truchon K., et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. Journal of Clinical Microbiology 2013, 51:571-577.
28. Colucci G., Ferguson J., Harkleroad C., et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. Journal of Clinical Microbiology 2007, 45:3595-3600.
29. Vermehren J., Colucci G., Gohl P., et al. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. Journal of Clinical Microbiology 2011, 49:3309-3315.
30. Elkady A., Tanaka Y., Kurbanov F., et al. Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4. Journal of Medical Virology 2010, 82:1878-1888.
31. LaRue H., Rigali L., Balada-Llasat J.M., et al. Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes. Journal of Clinical Microbiology 2012, 50:1769-1772.
32. Paba P., Fabeni L., Perno C.F., et al. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay. Journal of Virological Methods 2012, 179:77-80.
33. Sizmann D., Boeck C., Boelter J., et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. Journal of Clinical Virology 2007, 38:326-333.
34. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004, 140:346-355.
35. Jensen D.M., Morgan T.R., Marcellin P., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
36. Zeuzem S., Poordad F. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response. Current Medical Research and Opinion 2010, 26:1733-1743.
37. Muir A.J., Poordad F.F., McHutchison J.G., et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011, 54:1538-1546.
38. Susser S., Welsch C., Wang Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
39. Reesink H.W., Zeuzem S., Weegink C.J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002.
40. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
41. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132:1270-1278.
42. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine 2009, 360:1827-1838.
43. Kieffer T.L., Sarrazin C., Miller J.S., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631-639.
44. Bartels D.J., Zhou Y., Zhang E.Z., et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. Journal of Infectious Diseases 2008, 198:800-807.
45. Sarrazin C., Shiffman M.L., Hadziyannis S.J., et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. Journal of Hepatology 2010, 52:832-838.
46. Peiffer K.-H., Gerber L., Susser S., et al. Significant differences between different assays for assessment of HCV RNA undetectability during response guided therapy in patients treated with PEG-Interferon. Ribavirin with or without a protease inhibitor. Hepatology 2012, 56:560A.
47. Foster G., Hezode C., Bronowicki J., et al. Activity of telaprevir alone or in combination with peginterferon alpha-2a and ribavirin in treatment naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. Journal of Hepatology 2009, 50(Suppl. 1):S22.
48. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
49. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
50. Fevery B., Susser S., Lenz O., et al. Comparison of two quantitative HCV RNA assays in samples from patients treated with a protease inhibitor-based therapy: Implications for response guided therapy. Journal of Hepatology 2012, 56:S26.
51. Vermehren J., Aghemo A., Falconer K., et al. Undetectable HCV-RNA in telaprevir-treated patients: low concordance between two highly sensitive real-time PCR assays. Journal of Hepatology 2013, 58(Suppl.). [Abstract 506].
52. Maasoumy B., Cobb B., Halfon P., et al. A clinical trial evaluating low HCV RNA viremia in patients treated with triple therapy regimens: implications for patient management using different assys in clinical pratice. Journal of Hepatology 2013, 58. [Abstract 855].
53. Ferenci P., Asselah T., Foster G., et al. Faldaprevir plus pegylated Interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from Startverso1, a randomised, double-blind, placebo-controlle phase III trial. Journal of Hepatology 2013, 58. [Abstract 1416].
54. Manns M., Marcellin P., Poordad F. Simeprevir (TMC435) with PegInterferon/Ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. Journal of Hepatology 2013, 58. [Abstract 1413].
55. COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test. Version 2.0: EU Package insert. Doc Rev. 1.0; 2011.
56. COBAS® AmpliPrep/COBAS® TaqMan® HCV Test. v2.0: US package insert Doc Rev 1.0; 2013.
57. COBAS® TaqMan® HCV Test v2.0 For Use With The High Pure System. EU package insert. Doc Rev. 9.0; 2013.
58. COBAS® TaqMan® HCV Test v2.0 For Use With The High Pure System. US package insert. Doc Rev. 2.0; 2011.
59. Abbott RealTime HCV. EU package insert; 2006.
60. Abbott RealTime HCV. US package insert; 2011.